Skip to main content

GE stock rockets after $21 billion deal with Danaher, but remains below key chart level

Shares of General Electric Co. rocket after a deal to sell the company’s biopharma business for $21.4 billion in cash to Danaher Corp, but remain on track to extend their longest streak below the widely watched 200-day moving average in at least 40 years.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.